WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Tuesday, November 1, 2016

First clinical trial of CDNF in Parkinson's announced

November 1, 2016



Herantis Pharma, a Finnish pharmaceutical company, has announced the first clinical trial of a new treatment for Parkinson's.
It is great to see the innovation from the GDNF study already benefiting other clinical trials.
Dr Beckie Port, Senior Research Communications Officer
The study, due to start next year, will use a state of the art delivery system to get a compound called cerebral dopamine neurotrophic factor (or CDNF for short) delivered directly into the brain.
The study is currently being discussed with regulatory bodies in Finland and Sweden and aims to start recruiting people with Parkinson's in 2017.

What is CDNF?

CDNF is one of a family of 'growth factors' that the brain produces naturally to help cells to grow and survive.
Another important member of this family is GDNF (or glial cell line-derived neurotrophic factor) which is already being tested in a groundbreaking clinical trialsupported by Parkinson's UK.
Research suggests that CDNF can protect dopamine-producing cells and encourage them to grow again.
Getting CDNF to where it's needed in the brain requires an innovative delivery system. But one has already been developed and used successfully in our GDNF trial.
The company involved in helping to develop this drug delivery system for the GDNF trial is called Renishaw and they are now partnering with Herantis to use similar technology in the CDNF trial.

Urgent need for better treatments

Dr Beckie Port, Senior Research Communications Officer at Parkinson's UK, comments:
"Currently there is no treatment that can slow or stop the progression of Parkinson's. But there is a real hope that research will deliver new and better treatments that can do this. And it is great to see the innovation from the GDNF study already benefiting other clinical trials.
"Whilst the first clinical trial in people is a huge milestone for any new treatment, it's still early days for CDNF.
"This phase of the clinical trial will involve a small number of participants to learn about the safety of this new compound and it is some years away from being made available to people with the condition."
https://www.parkinsons.org.uk/news/1-november-2016/first-clinical-trial-cdnf-parkinsons-announced

No comments:

Post a Comment